



24 mortality risk of those without AKI. Diagnosis time after disease onset was 8.5 days (IQR, [4–  
25 11]). Fatality time after initial hospital admission was 13.5 days (IQR, 8–17). In non-survivors,  
26 systemic inflammation with high temperature, abnormal respiratory rate, acute myocardial  
27 injury, and acute respiratory distress syndrome (ARDS) were observed. Abnormal biochemical  
28 analytes and immunological markers were observed.

## 29 **Conclusion**

30 Our analyses indicate that patients experienced repeated changes in biochemical analytes and  
31 immune marker with the progression of the disease. It indicates the requirement of early  
32 management and treatment. Further study is required to conclude and to have better knowledge  
33 of AKI mechanism with COVID-19 infection.

34 **Keywords:** Acute kidney injury, COVID-19, Coronavirus, mortality, SARS-CoV-2, non-  
35 survivor, in-hospital death.

## 36 **Introduction**

37 As per worldometer report as of 8<sup>th</sup> June, 2023 there were 690,140,273 Coronavirus positive  
38 cases and 6,896,133 people were died [1]. The Coronavirus 2019 (COVID-19) disease outbreak  
39 occurred in Wuhan, Hubei Province, China, in December 2019, and rapidly spread to other areas  
40 of the worldwide. Now, it is well known that the novel Coronavirus is more dangerous than a  
41 common respiratory virus. Usually it targets the lungs, but it can attack the whole body.  
42 Physician observed that it can cause blood clot and multi organ failure. It was observed that a  
43 certain portion of COVID-19 affected patient develops acute kidney injury with normal  
44 creatinine level [6].

45 The SARS-CoV-2 virus affect the respiratory organ but based on clinical findings of several  
46 deceased cases the involvement of other organs needs to be explored [6]. Since information on

47 kidney disease in patients with COVID-19 is limited, in this meta-analysis we want to determine  
 48 the incidence of acute kidney injury (AKI) in patients with COVID-19 by pooling the available  
 49 published data. Further, we evaluated the association between markers of abnormal kidney  
 50 function and death in patients with COVID-19. Now, there are still no specific treatments or  
 51 vaccines for COVID-19 affected patient. We want to discuss possible pathogenic mechanism  
 52 which may shed light on future intervention.

### 53 **Material and methods**

54 We systematically reviewed the literature on COVID-19 and its association with acute kidney  
 55 injury symptoms. The systematic review was performed according to the Preferred Reporting  
 56 Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Table 1)[ 2].

57 **Table 1.** Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)  
 58 checklist.

Section/topic	#	Checklist item	Reported in main text on
<b>TITLE</b>			
Title	1	Connecting the Dots: Systematic Exploration of COVID-19 and Acute Kidney Injury through Meta-Analysis	p. 1
<b>ABSTRACT</b>			
Structured summary	2	structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	p. 1-2
<b>INTRODUCTION</b>			
Rationale	3	Rationale for the review in the context of what is already known.	p. 1-2
Objectives	4	Statement of questions are addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	p. 3
<b>METHODS</b>			
Protocol and registration	5	Review protocol	None
Eligibility criteria	6	Study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status)	p. 3
Information sources	7	All information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies).	p. 3
Search	8	Electronic search strategy.	Table 2
Study selection	9	Studies selected (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	p. 4
Data collection process	10	Method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p. 4

Data items	11	List of all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p. 4
Risk of bias in individual studies	12	Methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	p. 4
Summary measures	13	Principal summary measures (e.g., risk ratio, difference in means).	p. 4
Synthesis of results	14	Methods of handling data and combining results of studies, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	p. 5
Risk of bias across studies	15	Assessment of risk of bias.	p. 5
Additional analyses	16	Methods of additional analyses	None
<b>RESULTS</b>			
Study selection	17	Numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	p.4, Figure 1
Study characteristics	18	Characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and the citations.	Table 3, 4
Risk of bias within studies	19	Data on risk of bias of each study and outcome level assessment.	Figure 3, Table 7
Results of individual studies	20	Outcomes considered (benefits or harms) : (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, with a forest plot.	Table 5,6 Figure 2a,2b
Synthesis of results	21	Results of meta-analysis done, including confidence intervals and measures of consistency.	p. 4-5 Figure 2a,2b
Risk of bias across studies	22	Results of risk of bias across studies.	Figure 3 Table 7
Additional analysis	23	Results of additional analyses.	None
<b>DISCUSSION</b>			
Summary of evidence	24	Main findings including the strength of evidence for each main outcome.	p. 13
Limitations	25	Limitations at study and outcome level.	p. 16
Conclusions	26	A general interpretation of the results in the context of other evidence, and implications for future research.	p.16
<b>FUNDING</b>			
Funding	27	Sources of funding for the systematic review and other support.	p. 17

59

60 Two authors independently performed a literature search using PubMed, Web of Science,  
61 Embase, and Cochrane Library fulfilled the pre-specified criteria until 8th June, 2023 to include  
62 studies reported the necessary clinic characteristics, the incidence of AKI, the mortality with  
63 AKI and the death risk with AKI during COVID-19 infection were pooled for statistical analysis  
64 by MedCalc software [3] to get conclusions.

65 **Literature search**

66 A comprehensive literature search was performed using combination of keywords (MeSH terms  
67 and free text words) including ‘COVID-19’/ ‘SARS-CoV-2’, ‘AKI’/‘acute kidney injury’, and  
68 “English language”. PubMed, Embase, Cochrane library, Cochrane COVID-19 Study Register  
69 and DIRECTORY OF OPEN ACCESS JOURNALS(DOAJ) and Web of Science were searched  
70 up to 8th June 2023. The search strategy was present in Table 2. Additional articles were sought  
71 from the reference lists of the included studies.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91 Table 2. Search criteria for systematically reviewing COVID-19 and Acute kidney injury (AKI) in  
 92 PubMed, Embase Cochrane Library, Cochrane COVID-19 Study Register and Web of Science

ID	Search site	Key word	Search terms	Hits
#1	PubMed	COVID-19	(((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory	17,850
#2	PubMed	(COVID-19) AND (Acute Kidney Injury)	(((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])	78
#3	PubMed	Acute Kidney Injury) AND (SERS-CoV-2)	("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]	62063
#4	PubMed	((Acute Kidney Injury) AND (SERS-CoV-2)) OR (COVID-19)	((("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) OR ((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR ("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication])))	79835
#5	PubMed	Acute Kidney Injury	("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]	62063
#6	PubMed	SERS-CoV-2	it retrieved zero results.	0
#7	PubMed	AKI	("AKI"[All Fields]	13853
#8	PubMed	(Coronavirus disease 2019) AND (acute kidney injury)	((("covid 19"[Supplementary Concept] OR "covid 19"[All Fields]) OR "coronavirus disease 2019"[All Fields]) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])	85

#9	PubMed	((Coronavirus disease 2019) AND (acute kidney injury)) AND (English[Language])	((("covid 19"[Supplementary Concept] OR "covid 19"[All Fields]) OR "coronavirus disease 2019"[All Fields]) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])) AND "English"[Language]	81
#10	PubMed	((COVID-19) AND (acute kidney injury)) AND (English[Language])	((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language]	82
#11	PubMed	((novel coronavirus disease) AND (acute kidney injury)) AND (English[Language])	((("novel"[All Fields] OR "novel s"[All Fields]) OR "novels"[All Fields]) AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) OR "coronaviruses"[All Fields]) AND (((("disease"[MeSH Terms] OR "disease"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseased"[All Fields])) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language]	24
#12	PubMed	((COVID-19) AND (acute kidney injury)) AND (English[Language]) OR ((novel coronavirus disease) AND (acute kidney injury)) AND (English[Language])	((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language]) OR (((("novel"[All Fields] OR "novel s"[All Fields]) OR "novels"[All Fields]) AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) OR "coronaviruses"[All Fields]) AND (((("disease"[MeSH Terms] OR "disease"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseased"[All Fields])) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language])	88



#13	PubMed	((((COVID-19 AND (acute kidney injury)) AND (English[Language])) OR ((novel coronavirus disease) AND (acute kidney injury)) AND (English[Language]))	((((((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/5/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language]) OR (((("novel"[All Fields] OR "novel s"[All Fields]) OR "novels"[All Fields]) AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields] OR "coronaviruses"[All Fields]) AND (((("disease"[MeSH Terms] OR "disease"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseased"[All Fields])) AND (("acute kidney injury"[MeSH Terms] OR ("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) AND "English"[Language])	84
#14	Cochrane Library	COVID-19 AND AKI	(COVID-19):ti,ab,kw AND (Acute Kidney Injury):ti,ab,kw	5
#15	Cochrane Library	COVID-19 AND Acute Kidney Injury	(COVID-19 AND Acute Kidney Injury):ti,ab,kw (Word variations have been searched)	6
#16	Cochrane COVID-19 Study Register	COVID-19 and acute kidney injury	COVID-19 and acute kidney injury	1,711
#17	DIRECTORY OF OPEN ACCESS JOURNALS(DOAJ)	COVID-19 and acute kidney injury	COVID-19 and acute kidney injury	13
#20	Embase	COVID-19 AND acute kidney injury	"COVID-19 AND acute kidney injury" in journals	2,360
#21	Web of Science	COVID-19 AND acute kidney injury	(from Web of Science Core Collection)	24

93

94 **Selection criteria**

95 All articles identified from the literature search were screened by two independent reviewers

96 (M.S.S and R.J). We included studies on COVID-19 in adult patients. Full articles, Conferences



97 abstracts, Case reports, case series, non-randomized studies, randomized trials and observational  
98 studies, that were published in English were included in this review. Commentaries, letters to  
99 editors and editorials were also included. Studies on severe acute respiratory syndrome (SARS)  
100 and Middle East respiratory syndrome (MERS) but not COVID-19 were excluded.

### 101 **Data Collection**

102 For eligible studies, study information including first authors, site of study, inclusion and  
103 exclusion criteria, sample size, age and sex were recorded. A standardized form for data entry  
104 has been devised to focus on the following areas: number of patients, number of AKI patients,  
105 AKI related indicators (according to Acute Kidney Injury Network (AKIN): (a) an increase  
106 in the serum creatinine level to  $\geq 0.3$  mg/dL, (b) an increase in baseline serum creatinine level to  
107  $\geq 150\%$ )[4], AKI related death (Table 3 and 4).

108

109

110

111

112

113

114

115

116

117

118

119

120

121 Table 3. Characteristics of studies included in the systematic review (qualitative analysis).

SL#	Study name	Reference#	Journal	Date of Publication	Study Population (n)	Age in Years (range)	Sex	
							M, n (%)	F, n (%)
1	Lim et al.,	4	J. Clin. Med	3 June 2020	160	69.0 (24.0-98.0)	88 (55)	72 (55)
2	Shao et al.,	5	Front. Med	22 May 2020	155	48.0 (7.0–96.0)	62(40)	93(60)
3	Cheng et al.,	6	Kidney International	16 March 2020	701	63.0 (50.0–71.0)	367(52.4)	334(47.7)
4	Wang et al	7	Critical Care	30 April 2020	107	51.0 (19.0–92.0)	57 (53.3)	44(46.7)

122

123

124

125

126

127

128

129

130

131

132

133 Table 4: Characteristics of studies included in the systematic review (Quantitative analysis)

Reference	Authors	Journal	Date of Publication	Study population	AKI definition	AKI related death	AKI	Baseline creatinine	Blood Urea Nitrogen (BUN)	Proteinuria	Hematuria	eGFR	D-dimer	RRT(n)
4	Lim et al.,	J. Clin. Med	3 June 2020	164	AKIN	17	30	30/30	30/160	N/A	N/A	30/30	16/30	CRRT (5)
5	Shao et al.,	Front. Med	22 May 2020	155	N/A	7	7	18/155	18/155	N/A	N/A	N/A	18/155	CRRT (7)
6	Cheng et al.,	Kidney International	16 March 2020	701	KDIGO	HR	36	36/36	701	194/442	118/442	701/701	512/661	N/A
7	Wang et al	Critical Care	30 April 2020	107	KDIGO	OR	14	107	N/A	N/A	N/A	N/A	107	CRRT (4)
8	Li et al.	The Lancet Infectious Diseases	2020	193	KDIGO	HR	55	43/193	59/193	88/147	71/147	N/A	128/182	CRRT (7)

134

135 Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; RRT, Renal Replacement Therapy, (n) indicate number of  
 136 patients received RRT, CRRT, continuous renal replacement therapy; KDIGO, Kidney Disease: Improving Global Outcomes; HR, Hazard Ratio,  
 137 OR, Odd Ratio,

138

139

140 **Data synthesis and statistical analysis**

141 Primary outcomes of our study included acute kidney injury (AKI) in COVID-19 infected patient (Table 5),

142 Table 5. Incidence of AKI patient those who were SARS-CoV-2 positive

SL #	Study name	Ref#	AKI(n)	Total Death (n)	Non-AKI(n)	Death in non-AKI (n)	Total	Prevalence (%)	Weight (%)	Risk Ratio
1	Lim et al.,2020	4	17	30	134	13	164	10.37	12.42	6.6
2	Shao et al.,2020	5	7	18	137	11	155	4.52	11.74	5.1
3	Cheng et al., 2020	6	36	113	588	77	701	13.08	8.11	15.0
4	Wang et al, 2020	7	14	19	88	5	107	5.14	53.11	2.6
5	Li et al.,2020	8	32	55	138	23	170	28.50	14.62	4.3
	Total		106	235	1085	129	1320	8	100	4.1

143

144 death of AKI developed patients (Table 6),

145 Table 6. Death in acute kidney injury patient who were SARS-COV-2 infected

#	Study name	Ref#	Death (n)	AKI(n)	Prevalence (%)	Weight (%)
1	Lim et al.,	4	17	30	56.67	18.99
2	Liang et al.,	5	7	18	38.89	11.39
3	Cheng et al.,	6	6	36	16.67	22.78
4	Wang et al.,	7	14	19	73.68	12.03
5	Li et al.	8	32	55	58.18	34.81

146

147

148

149 clinical symptoms, markers of kidney injury. For the AKI prevalence rates, data were pool  
150 analyzed using SPSS and MedCalc. When there are two or more studies with at least four  
151 patients reporting the same outcome under the same definition, random effects model was used.  
152 Double arcsine transformation was used to pool the proportions. The results were presented by  
153 forest plots (Figure 2a,b),

154

155

156

157


158

159

160

161

162



163 Figure 2.a: Prevalence of Death in AKI patient those who were SERS-CoV-2 positive

164

165

166

167


168

169

170

171

$Q=25.30, P < 0.0001, I^2=84.19\%$



172 Figure 2b: Death in acute kidney injury patient who were SERS-COV-2 infected

173 illustrating the prevalence, 95% confidence intervals and weightings. Cochran's Q test was used  
174 to detect heterogeneity, and a  $p$  value of  $< 0.10$  indicates significant heterogeneity.  $I^2$  statistics  
175 was calculated to measure the proportion of total variation in study estimates attributed to  
176 heterogeneity with  $I^2 > 50\%$  suggests substantial heterogeneity.

## 177 **Results**

178 The PRISMA flow diagram was shown in Figure 1. A total of 1723 records were identified upon  
179 literature search, and 11 additional records were sought from reference lists of the included  
180 literature. 1535 records remained after removing duplicates. Among them, 757 were screened  
181 and 816 were excluded (641 not related and 135 review articles). Of the screened articles 108  
182 were assessed for eligibility (COVID-19 and AKI) and 649 were excluded as not related to AKI.  
183 Of the 108 articles only 5 were eligible for serum creatinine marker. These five articles were  
184 selected for quantitative analysis [4-8]. Using funnel plot one study was excluded and the  
185 remaining four were selected for qualitative analysis. Table 3 give a clear picture of basic  
186 characteristics of the 4 studies [4,6-8] that were included in the qualitative analysis. The  
187 Newcastle-Ottawa score of the included studies is shown in Table 7.

188 **Table 7. Results of quality assessment for risk of selection bias as per Newcastle-Ottawa Scale**

Author, year	Age	Gender	Sampling method	Location	Author, year	Total scores	Risk of selection bias
Lim, J.-H,2020	1	1	1	1	1	5	Low risk
Liang Shao,2020	1	1	1	1	1	5	Low risk
Cheng Y,2020	1	1	1	1	1	5	Low risk
Wang et al,2020	1	1	1	1	1	5	Low risk

189

190

191

192

193

194 Publication bias was shown in the funnel plot analysis in Figure 3.

195

196 Funnel Plot

197 Fu

198

199

200

201


202

203

204

205

206



207

208 Figure 3. Funnel plot to select study for qualitative analysis

209

210 There was no evidence of publication bias when applying funnel plot analysis (Figure 3). As per

211 our meta-analysis it was observed that mortality is remarkably higher in COVID-19 infected

212 patients with severe AKI. At present, scientists observed the incidence of AKI among patients

213 with COVID-19 with varying conclusion. It was observed to occur nearly one in four of patients

214 with COVID-19 [9]. Our meta-analysis included five studies and the findings are discussed

215 below:

216 **High mortality in older male patient:**

217 We have included five studies for our analysis. Of these five all of them reported older age and

218 male sex were risk factors for patient illness. We were able to extract data from three studies.



219 The study by Lim et al., reported of the non-survivor median age was 75.0 years and about 67%  
220 were male [4]. Shao et al., observed that of the non-survivors, the median age was 73.5 years,  
221 and the proportion of males was 72.2% [5]. Wang et al., also reported the same findings [of the  
222 non-survivors(n=19) were of 73.0 years and 84.2% (16/19) were male] [7].

223

#### 224 **In-hospital mortality was higher in AKI patients:**

225 All of the studies observed most case fatality in AKI patient specially in stage III AKI group who  
226 needed renal replacement therapy. Study of Li et al. reported by Cox regression analysis that  
227 COVID-19 patients who developed AKI had a ~5.3-times mortality risk of those without AKI  
228 [8].

229

#### 230 **The interval between disease onset and Diagnosis:**

231 The incubation period of COVID-19 is considered to be up to 14 days following exposure [10-  
232 12]. Two studies highlighted on this issue. Cheng et al and Wang et al., define the date of disease  
233 onset was the day when the first symptom was noticed [7]. Wang et al also informed that  
234 “median duration from illness onset to admission was 10 days”. Shao et al.; observed that  
235 ‘diagnosis time after disease onset was 8.5 days (IQR, [4–11]) [5]. Lim et al. reported that there  
236 were 17 deaths among AKI patients; [stage-I: 4 (28.6%), stageII: 1 (25.0%), and stageIII: 12  
237 (100.0%), respectively] [4]. It was also mentioned in the same article that in-hospital mortality  
238 was higher in AKI patients than in non-AKI patients (56.7% vs. 20.8%,  $p < 0.001$ ) [4]. It was  
239 observed that there was more death in stage 3 AKI than non-AKI or stage 1 AKI (hazard  
240 ratio (HR) = 3.62 (95% confidence interval (CI) = 1.75–7.48),  $p = 0.001$ ; HR = 15.65

241 (95% CI = 2.43–100.64),  $p = 0.004$ ). Using Kaplan–Meier analysis Cheng et.al, showed that  
242 patients with kidney disease had a significantly higher risk for in-hospital death. Cox  
243 proportional hazard regression established that AKI stage 1(hazard ratio: 1.90, 95% confidence  
244 interval: 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31) [6].

#### 245 **Fatality time:**

246 Two studies reported about the fatality time form onset of illness to death. Shao et al observed a  
247 “period of 7–13 days after illness onset is the critical stage in the COVID-19 course. All patients  
248 died within 45 days after the initial hospital admission with a median survivor time of 13.5 days  
249 (IQR, 8–17)” [5]. Cheng et al., also support similar findings and observed that the prevalence of  
250 kidney disease on admission and the development of AKI during hospitalization in patients with  
251 COVID-19 is high and is associated with in-hospital mortality [6].

252

#### 253 **Inflammation in AKI and acute respiratory distress syndrome**

254 Wang et al; observed in non-survivors, the appearance of systemic inflammation with high  
255 temperature, abnormal respiratory rate, WBC counts and neutrophil counts. Subsequently,  
256 multiple organ dysfunction syndromes (MODS) occurred with thrombocytopenia, renal failure,  
257 acute myocardial injury, and ARDS [7].

258

#### 259 **Biochemical parameters:**

260 The following abnormal biochemical parameter were observed in COVID-19 patient with AKI:

#### 261 **Elevated baseline serum creatinine:**

262 The baseline serum creatinine level was defined as the serum creatinine value on admission or  
263 within 6 months before admission [4]. The typical reference range for serum creatinine is 60 to

264 110 micromoles per liter ( $\mu\text{mol/L}$ ) (0.7 to 1.2 milligrams per deciliter ( $\text{mg/dL}$ )) for men and 45  
265 to 90  $\mu\text{mol/L}$  (0.5 to 1.0  $\text{mg/dL}$ ) for women [13]. Four studies observed elevated serum  
266 creatinine in AKI patient [5-8]. Shao et al., observed an elevated serum creatinine level at day of  
267 admission and day of death. [88.25  $\mu\text{mol/L}$  (76.70–123.70) and 123.60 (70.80–328.70)  
268 respectively, median and IQR]. Cheng Y also observed nearly fifteen percent of the patient on  
269 admission had elevated serum creatinine ( $77\pm 31$ , mean  $\pm$  SD). In this study cox proportional  
270 hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95%  
271 confidence interval: 1.36-3.26) was independent risk factor for in-hospital death. Wang et al.,  
272 and Li et al., also observed the same situation.

273

#### 274 **Elevated baseline blood urea nitrogen**

275 Blood urea nitrogen (BUN) normal reference range for adults is 3.6-7.1  $\text{mmol/L}$ [14]. Cheng et  
276 al., observed 13.1% patient has elevated BUN during admission and the whole course of  
277 treatment. Cox proportional hazard regression confirmed that elevated baseline blood urea  
278 nitrogen (hazard ratio: 3.97, 95% confidence interval: 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76),  
279 stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31) was independent risk factor for in-hospital  
280 death. Wang et al., and Li et al., also observed the same situation. Wang et al., observed  
281 admission values of blood urea nitrogen were elevated in the non-survivors. Li et al., observed  
282 “On hospital admission, a remarkable fraction of patients had signs of kidney dysfunctions,  
283 including 14% with increased levels of blood urea nitrogen” [8].

#### 284 **Estimated Glomerular Filtration Rate (eGFR)**

285 A normal eGFR for adults is greater than 90  $\text{mL/min/1.73m}^2$ , according to the National Kidney  
286 Foundation and actual numbers are only reported once values are less than 60  $\text{mL/min/1.73m}^2$ .[

287 15] The study by Cheng et al., reported during admission 13.1% patients had reduced eGFR (<  
288 60 ml/min/1.73m<sup>2</sup>).

289

### 290 **High level of D-dimer**

291 D-dimer is a protein fragments formed when a blood clot gets dissolved in blood stream. Acute  
292 kidney injury (AKI) affects the hypercoagulable state [16] of the body. As coagulation  
293 biomarkers D-dimer is measured. It's normal value is 0–500 mg/L and Shao et al., observed an  
294 extremely high level of D-dimer on the death date compared with the admission date (median,  
295 3542.50 [IQR, 2797.00–10929.00] vs. 492.50 [IQR, 273.00–2139.00], p<0.05). Cheng et al.,  
296 observed an elevated D-dimer on 77.5 % COVID-19 patients during admission. Wang et al.,  
297 observed the non-survivors had higher D-dimer level (439 mg/L [202–1991]vs 191 mg/L [108–  
298 327], P = 0.003) in COVID-19 patients. Li et al., showed that using univariate cox regression  
299 analysis, D-dimer were significantly associated with the death of COVID-19 patient [5-8].

### 300 **Proteinuria**

301 Patient with proteinuria have urine containing an unusual amount of protein. The condition is a  
302 signal of kidney disease. During acute kidney injury albumin leak form the damage kidney filters  
303 into the urine [17]. The normal mean albumin excretion rate (AER) is 5-10 mg/day, with an AER  
304 of >30 mg/day considered abnormal [18].In this review we included five studies and two of them  
305 highlighted on proteinuria in AKI patient. Cheng et al., observed that during hospital admission,  
306 almost half of patients had proteinuria. One in twenty patient developed AKI during the study  
307 period. Kaplan–Meier analysis confirmed that patients with kidney disease had a top risk for in-  
308 hospital death. Cox proportional hazard regression support that proteinuria 1+ (hazard ratio:  
309 1.80, 95% confidence interval: 0.81-4.00), 2+~3+(4.84, 2.00-11.70), had independent risk factors

310 for in-hospital death [6]. Study by Li et al., also observed during hospital admission, more than  
311 half of patients had proteinuria. The univariate cox regression analysis confirms that proteinuria  
312 was remarkably associated with the fatality of COVID-19 patients [8].

313

### 314 **Hematuria**

315 Hematuria is defined as the presence of 5 or more red blood cells (RBCs) per high-power field in  
316 3 of 3 consecutive centrifuged specimens available at least 1 week apart. It can be either visible  
317 or microscopic. It may also be either symptomatic or asymptomatic, either temporary or  
318 constant, and either alone or coupled with proteinuria and other urinary problem [19]. Two of  
319 our analyzed studies informed on hematuria in AKI patient. Cheng et al., observed that almost  
320 one in four patients had hematuria during hospital admission. During the study period, AKI  
321 occurred in almost five percent patients. It was observed that the AKI patient had a top risk for  
322 in-hospital mortality by Kaplan–Meier analysis. Cox proportional hazard regression analysis  
323 confirmed that hematuria 1+(hazard ratio: 2.99, 95% confidence interval: 1.39-6.42), 2+~3+  
324 (5.56,2.58- 12.01) were independent risk factors for in-hospital death [6]”. Study by Li et al.,  
325 also support such observation. They showed during hospital admission, nearly half of patients  
326 had hematuria. The univariate cox regression analysis confirms that hematuria was remarkably  
327 associated with the casualty of COVID-19 patients [8].

328

### 329 **Immune parameters**

#### 330 **Hematological parameter**

331 Shao et al., observed that “with the deterioration of disease, most patients experienced  
332 consecutive changes in lymphopenia, leukocytosis, thrombocytopenia. Regarding the immune

333 dysregulation, patients exhibited significantly decreased T lymphocytes in the peripheral blood,  
334 including CD3+T, CD3+CD4+Th, and CD3+CD8+Tc cells”. Wang et al., reported “in severe  
335 cases, leukocytosis, neutrophilia, and deteriorating multi-organ dysfunction were dominant” [5].  
336 The role of cytokine is well known by scientific community in viral infection. None of our  
337 included studies analyzed cytokine profile. We reviewed literature about cytokine in SARS-  
338 CoV-2 infection which is discussed below:

339

#### 340 **Cytokine Storm in SARS-CoV-2 Infection**

341 Abnormalities of the inflammatory cytokines profile are good trait during SARS-CoV infection.  
342 They correlate with illness but poor prognostic marker [20-21]. Many studies observed a group of  
343 patients with COVID-19 had inflammatory response and cytokine storm syndrome [22-24]. A  
344 cytokine profile with hyper-inflammatory condition defined by a huge cytokine production and  
345 serious problem with vital organs failure was observed in COVID-19 patients. In addition,  
346 increased ferritin and IL-6 levels observed in more than hundred confirmed COVID-19 cases. It  
347 indicates that virus related hyper-inflammation might be one leading cause of serious health  
348 problem [25].


349 In a cohort of 53 patients with COVID-19 compared to healthy controls a marked increase of 14  
350 pro- and anti-inflammatory cytokines were observed. Among them, interferon gamma induced  
351 protein 10(IP-10), monocyte chemotactic protein-3(MCP-3) and interleukin (IL-1ra) were  
352 significantly associated with disease severity [23]. It supports that abnormal inflammatory  
353 cytokine release was dangerous for lung tissue injury and COVID-19 pathogenesis.

354

355

356 **Possible Pathophysiology of AKI in COVID-19**

357 The cause of kidney injury in COVID-19 is thought to be complex [43]. It is related to  
358 cardiovascular comorbidity and influencing factors like nephrotoxin, bacteremia and  
359 hypovolemia. The right ventricular failure due to COVID-19 pneumonia cause kidney  
360 congestion following AKI. Also, left ventricular abnormalities generate low cardiac function,  
361 arterial under filling, and kidney hypoperfusion. The endothelium of lung and kidney is disrupted  
362 which cause proteinuria. Additionally, virus particles were present in renal endothelial cells as  
363 indicated by postmortem report. So, viremia is a possible cause of endothelial damage in the  
364 kidney and a probable contributor to AKI [44]. A schematic diagram is drawn in figure 4 to  
365 represent the possible pathophysiology of AKI in SARS-CoV-2 infection.



366

367 **Figure-4: Mechanism of acute kidney injury in COVID-19 infection**

368

369 Furthermore, SARS-CoV-2 can directly infect the renal tubular epithelium and podocytes  
370 through an angiotensin converting enzyme 2 (ACE2)-dependent pathway. It causes acute tubular  
371 necrosis, mitochondrial abnormalities, the formation of protein reabsorption vacuoles, collapsing



372 glomerulopathy, and protein leakage in Bowman's capsule [45,46]. Another immunological  
373 mechanism is also discussed nowadays in scientific community related to AKI. Reduced  
374 lymphocyte count and elevated cytokine production is thought to be related to AKI [47,48].

### 375 **Discussions**

376 COVID-19, the disease caused by the novel coronavirus, affected 213 countries of the world. It  
377 has infected nearly seven million people and almost half a million died. The coronavirus 2019  
378 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, in December 2019,  
379 and rapidly spread to other areas of the worldwide. Now, it is well known that the novel  
380 coronavirus is dangerous than a simple respiratory virus. Usually it targets the lungs, but it can  
381 attack the whole body. Physician observed that it can cause blood clot and multi organ failure. It  
382 was observed that a certain portion of COVID-19 affected patient develop acute kidney injury  
383 with normal creatinine level. Thus, it bypasses the screening criteria and by this time the fatality  
384 occurred[6].

385 Our meta-analysis provided evidence that the incidence of AKI in hospitalized patients with  
386 COVID-19 infection is low, only about 8%. On the other hand, this AKI incidence during this  
387 viral infection provides a strong danger signal: the in-hospital mortality in AKI with COVID-19  
388 infected patients is bigger, which is up to 45%. Also the fatality risk with AKI in COVID-19  
389 infected patients is extremely high. Based on our pooled calculation it is about 4 times higher  
390 than those without AKI. Thus, clinicians should pay special attention to the treatment of COVID-  
391 19 patients with severe AKI.

392

393 We have analysed five studies and all of them reported older age and male sex were risk factors  
394 for COVID-19. This finding is consistent with other studies. In a case series studies at Wuhan

395 Union Hospital , Beijing , China from January 29, 2020 to February 15, 2020 with COVID-19  
396 infected 43 patients, observed older patients ( $\geq 65$  years old), were more likely to have a severe  
397 type of COVID-19. Males develop more severe cases than females. In the comparable public  
398 data set of COVID-19, they also found that the percentage of older age ( $\geq 65$  years) was much  
399 higher in the dead patients than who survived (83.8% in 37 deceased patients vs. 13.2% in 1,019  
400 patients who survived) [26]. The number of men is about two and half times higher than that of  
401 women in the dead patients. Although men and women had the same vulnerability, male were  
402 more prone to dying. Therefore, gender has a vital role in case fatality with COVID-19. This  
403 gender factor, as well as higher incidences in men for most of the diseases could correlate with a  
404 general demographic fact of a shorter life expectancy in men compared to women in China and  
405 in the world in general. Other studies from Beijing Municipal Medical Taskforce informed that  
406 SARS-CoV-2 attack cells via the angiotensin-converting enzyme 2 (ACE2) receptor. It was  
407 reported earlier that high protein expression of ACE2 receptor in specific organs correlated with  
408 specific organ failures, indicated by corresponding clinical parameters in SARS patients [27, 28].  
409 Also, it was reported earlier that circulating ACE2 levels are higher in men than in women [29].  
410 In-hospital mortality was higher in our analyzed AKI patients. Multiple organ dysfunction  
411 including the liver, gastrointestinal tract and kidney have been reported in patients with COVID-  
412 19[24, 30]. One possible cause is that some of the COVID-19 patients had a history of chronic  
413 kidney disease (CKD). Also, it was observed by some studies that the median time period  
414 between the first symptoms and signs of COVID-19 and hospital admission was around a week  
415 [8]. By this time the patients developed a pro-inflammatory condition with abnormalities in  
416 cellular populations specially the immune cells [30]. Also, there is a higher risk for upper  
417 respiratory tract infection [31] and pneumonia. [32].Cheng et al., also explained that many

418 COVID-19 patients could not be admitted in the early stage of disease due to lack of hospital  
419 beds. Earlier admission to hospital can help physician for management of the patient and disease  
420 spread to prevent nosocomial infection [8].

421  
422 There are several evidence that severe COVID-19 patients have high level of inflammatory  
423 cytokines such as IL-1RA, IL-7, IL-8, IL-9, IL-10 [33,20]. These cytokines may contribute to  
424 develop AKI in COVID19 patients. These cytokines interact with kidney cells and trigger  
425 endothelial and tubular abnormalities. It was reported that TNF- $\alpha$  can bind to tubular cell  
426 receptors. As a result, it also triggers the death receptor pathway of apoptosis [34]. Also other  
427 studies experienced an elevated IL-6 in seriously ill patients with COVID-19. They observed an  
428 increased IL-6 levels in deceased patient than to survivors [35]. The lethal role of IL-6 has been  
429 demonstrated in different models [36,37]. Therefore, we can assume that these cytokines may  
430 participate to AKI in COVID-19 patients.

431 We found that COVID-19 patients also generally exhibited kidney disorder with elevated levels  
432 of serum creatinine, BUN followed by proteinuria & hematuria. The occurrence of kidney  
433 disorder in COVID-19 patients might be explained because of the following reasons. The SARS-  
434 CoV-2 uses angiotensin-converting enzyme 2(ACE2) as a cell entry receptor [38]. This receptor  
435 expressed in a huge amount in the small intestine, testis, kidneys, heart, thyroid, and adipose  
436 tissue [39]. Also, this receptor expressed with a much-elevated level in kidney than that in the  
437 lung [8]. Therefore, it is likely that SARS-CoV-2 can also attack kidney epithelial cells in  
438 addition to attacking lung epithelial cells [40]. This finding was supported by a recent histology  
439 report of renal tissues from autopsies and found acute renal tubular damage in six COVID-19

440 cases [9]. (ii) kidney disorder with other organ can enhance the inflammation process in which  
441 injury and death of renal tubular epithelial cells occurred [41,42].

442

443 **Limitation:** This study has some limitations. The number of patients with AKI was small. Of  
444 the included studies a large majority are from China and the findings of this analysis may not be  
445 applicable to other part of the world. Clinical data of patient after release from hospital was  
446 absent, so we could not evaluate COVID-19 effects on long-term impact on health. More studies  
447 are needed to better investigate the risk of AKI and mortality in COVID-19 patients.

448

#### 449 **Conclusion**

450 Based on the available limited published data, severe AKI in patients with COVID-19 is a  
451 threatening clinical predictor and is associated with high mortality. Further studies are needed to  
452 understand the factors associated with worse outcomes among COVID-19 patients with AKI.  
453 Understanding those factors may guide care providers in making more informed dialysis  
454 eligibility decisions under conditions where resources are extremely limited.

455

#### 456 **Abbreviations**

457 AKI: acute kidney injury ; COVID-19: Corona Virus Disease 2019; PRISMA: Preferred  
458 Reporting Items for Systematic Reviews and Meta-Analyses; MODS: Multiple Organ  
459 Dysfunction Syndromes; ARDS: Acute Respiratory Distress Syndrome; BUN: Blood Urea  
460 Nitrogen; eGFR: Estimated Glomerular Filtration Rate.

461

462

463 **Declarations**

464 **Ethics approval and consent to participate**

465 Not applicable

466 **Consent for publication**

467 Not applicable.

468 **Availability of data and materials**

469 Not applicable.

470 **Competing interests**

471 The authors declare that they have no competing interests.

472 **Funding**

473 None

474 **Authors' contributions**

475 Conceptualization: MSS and RJ. Data curation: RJ. Investigation: MSS and RJ. Supervision and

476 visualization: MSS. Writing – original draft preparation: MSS and RJ. Writing – Review &

477 Editing: MSS and RJ. All authors have read and approved the final manuscript.

478

479 **Acknowledgments**

480 Not applicable

481 **Authors' information**

482 Not applicable.

483

484

485

486 **References**

487 1. Worldometers. COVID-19 Coronavirus Pandemic. Available from:

488 <https://www.worldometers.info/coronavirus/> [Accessed 8 June 2023].

489

490 2. Moher D, Liberati A, Tetzla J, Altman DG (2009) Preferred reporting items for systematic

491 reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535.

492

493 3. MedCalc Software. MedCalc statistical software version 16.4. 3.[computer software].

494

495 4. Lim JH, Park SH, Jeon Y, Cho JH, Jung HY, Choi JY, Kim CD, Lee YH, Seo H, Lee J, Kwon

496 KT. Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury. *Journal of*

497 *Clinical Medicine*. 2020 Jun;9(6):1718.

498

499 5. Shao L, Li X, Zhou Y, Yu Y, Liu Y, Liu M, Zhang R, Zhang H, Wang X, Zhou F. Novel

500 Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19.

501 *Frontiers in Medicine*. 2020 May 22; 7:246.

502

503 6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney

504 disease is associated with in-hospital death of patients with COVID-19. *Kidney international*.

505 2020 Mar 20.

506

- 507 7. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, Jian M, Xu H, Prowle J, Hu B, Li Y. Clinical  
508 course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2,  
509 discharged from two hospitals in Wuhan, China. *Critical Care*. 2020 Dec; 24:1-9.  
510
- 511 8. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, Li J, Duan G, Zhou Y, Wu X, Zhou Z. Caution on  
512 kidney dysfunctions of COVID-19 patients.  
513
- 514 9. Diao B, Feng Z, Wang C, Wang H, Liu L, Wang C, Wang R, Liu Y, Liu Y, Wang G, Yuan Z.  
515 Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-  
516 CoV-2) infection. *MedRxiv*. 2020 Jan 1.  
517
- 518 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing  
519 X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia.  
520 *New England Journal of Medicine*. 2020 Jan 29.  
521
- 522 11. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi  
523 HW. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating  
524 person-to-person transmission: a study of a family cluster. *The Lancet*. 2020 Feb  
525 15;395(10223):514-23.  
526
- 527 12. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, Dean N, Longini I, Halloran ME, Xu B,  
528 Zhang X. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China.  
529 *MedRxiv*. 2020 Jan 1.



530

531 13. Shimada M. BMJ Best practice, Assessment of elevated creatinine. Available from:

532 <https://bestpractice.bmj.com/topics/en-gb/935> [Accessed 13 June 2020].

533

534 14. Pagana KD, Pagana TJ. Mosby's Manual of Diagnostic and Laboratory Tests-E-Book.

535 Elsevier Health Sciences; 2017 Oct 8.

536

537 15. American Association for Clinical Chemistry (AACC), Estimated Glomerular Filtration Rate

538 (eGFR). Available from: [https://labtestsonline.org/tests/estimated-glomerular-filtration-rate-](https://labtestsonline.org/tests/estimated-glomerular-filtration-rate-egfr)

539 [egfr](https://labtestsonline.org/tests/estimated-glomerular-filtration-rate-egfr)). [Accessed 13 June 2020].

540

541 16. Huang MJ, Wei RB, Su TY, Wang Y, Li QP, Yang X, Lv XM, Chen XM. Impact of acute

542 kidney injury on coagulation in adult minimal change nephropathy. *Medicine*. 2016 Nov;95(46).

543

544 17. Khatri M. Proteinuria. WebMD LLC, [Online]. Available: [https://www.webmd.com/a-to-z-](https://www.webmd.com/a-to-z-guides/qa/what-is-proteinuria)

545 [guides/qa/what-is-proteinuria](https://www.webmd.com/a-to-z-guides/qa/what-is-proteinuria). [Accessed 13 June 2020]. 2015.

546

547 18. Lerma EV. Proteinuria. WebMD LLC, [Online]. Available: [http://emedicine.medscape.](http://emedicine.medscape.com/article/238158-overview)

548 [com/article/238158-overview](http://emedicine.medscape.com/article/238158-overview). [Accessed 29 August 2016]. 2015.

549

550 19. Bignall ONR, 2nd, Dixon BP. Management of Hematuria in Children. *Curr Treat Options*

551 *Pediatr*. 2018;4(3):333-49.

552

- 553 20. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and  
554 consequences of cytokine storm and immunopathology. *Semin Immunopathol.* 2017;39(5):529-  
555 39.
- 556
- 557 21. Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of  
558 pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-  
559 19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020 Mar  
560 14;34(2):1.
- 561
- 562 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z.  
563 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet.*  
564 2020 Feb 15;395(10223):497-506.
- 565
- 566 23. Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, Li G, Li Y, Xing L, Peng L, Wei J.  
567 Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated  
568 with disease severity and fatal outcome. *MedRxiv.* 2020 Jan 1.
- 569
- 570 24. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.  
571 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in  
572 Wuhan, China: a descriptive study. *The Lancet.* 2020 Feb 15;395(10223):507-13.
- 573

- 574 25. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-  
575 19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive care medicine*.  
576 2020 May;46(5):846-8.
- 577 26. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK. Gender differences in  
578 patients with COVID-19: Focus on severity and mortality. *Frontiers in Public Health*. 2020 Apr  
579 29;8:152.
- 580
- 581 27. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and  
582 diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabet*  
583 *Med*. 2006;23(6):623-8.
- 584
- 585 28. Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages  
586 islets and causes acute diabetes. *Acta Diabetol*. 2010;47(3):193-9.
- 587 29. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does  
588 angiotensin-converting enzyme 2 fit in? *Clin Exp Pharmacol Physiol*. 2013;40(8):551-9.
- 589
- 590 30. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. *Nature*  
591 *Reviews Nephrology*. 2013 May;9(5):255.
- 592
- 593 31. Cohen-Hagai K, Rozenberg I, Korzets ZE, Zitman-Gal T, Einbinder Y, Benchetrit S. Upper  
594 respiratory tract infection among Dialysis patients. *Isr. Med. Assoc. J*. 2016 Sep 1;18:557-60.
- 595

596 32.Sibbel S, Sato R, Hunt A, Turenne W, Brunelli SM. The clinical and economic burden of  
597 pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational  
598 cohort study. *BMC nephrology*. 2016 Dec 1;17(1):199.

599

600 33.Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in  
601 critically ill patients with COVID-19. *Intensive Care Medicine*. 2020 Jun 12:1-0.

602

603 34.Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in  
604 endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. *The Journal of*  
605 *Immunology*. 2002 Jun 1;168(11):5817-23.

606

607 35.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical  
608 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a  
609 retrospective cohort study. *The lancet*. 2020 Mar 11.

610

611 36.Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an  
612 update. *Frontiers in immunology*. 2017 Apr 21; 8:405.

613

614 37.Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH. IL-  
615 6/IL-6R axis plays a critical role in acute kidney injury. *Journal of the American Society of*  
616 *Nephrology*. 2008 Jun 1;19(6):1106-15.

617

618 38.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,  
619 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin.  
620 nature. 2020 Mar;579(7798):270-3.

621  
622 39.Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2  
623 in a wide variety of human tissues. Infectious diseases of poverty. 2020 Dec;9:1-7.

624  
625 40.Yeung ML, Yao Y, Jia L, Chan JF, Chan KH, Cheung KF, Chen H, Poon VK, Tsang AK, To  
626 KK, Yiu MK. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7  
627 and FGF2. Nature microbiology. 2016 Feb 22;1(3):1-8.

628  
629 41.Faubel S, Edelstein CL. Mechanisms and mediators of lung injury after acute kidney injury.  
630 Nature Reviews Nephrology. 2016 Jan;12(1):48.

631  
632 42.Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of  
633 organ dysfunction in multiple organ dysfunction syndrome. The American journal of emergency  
634 medicine. 2008 Jul 1;26(6):711-5.

635  
636 43.Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with  
637 COVID-19. The Lancet Respiratory Medicine. 2020 May 14.

638

- 639 44.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR,  
640 Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-  
641 19. *The Lancet*. 2020 May 2;395(10234):1417-8.  
642
- 643 45.Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C.  
644 Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.  
645 *Kidney international*. 2020 Apr 9.  
646
- 647 46.Larsen CP, Bourne TD, Wilson JD, Saqqa O, Moh'd A S. Collapsing Glomerulopathy in a  
648 Patient With COVID-19. *Kidney international reports*. 2020 Jun 1;5(6):935-9.  
649
- 650 47.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical  
651 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a  
652 retrospective cohort study. *The lancet*. 2020 Mar 11.  
653
- 654 48.Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal  
655 therapies. *Nature Reviews Nephrology*. 2020 Apr 9:1-3.